acute myeloid leukemia

News
Integrated Palliative and Oncology Care for AML Recommended as New Standard of Care
01/05/2021
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.
Integrated palliative and...
01/05/2021
Journal of Clinical Pathways
Conference Coverage
Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting
12/06/2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study...
12/06/2020
Journal of Clinical Pathways
News
Economic, Clinical Burden of AML Treatment Episodes in Commercially Insured Patients
07/02/2020
A new retrospective analysis highlights a “substantial economic burden” associated with key acute myeloid leukemia (AML) treatment episodes in commercially insured patients. Results of the analysis were published in...
A new retrospective analysis highlights a “substantial economic burden” associated with key acute myeloid leukemia (AML) treatment episodes in commercially insured patients. Results of the analysis were published in...
A new...
07/02/2020
Journal of Clinical Pathways
News
Impact of NGS on Treatment Selection in AML
06/08/2020
Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...
Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...
...
06/08/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up Data Supports Frontline Treatment Option for Older AML Patients
05/21/2020
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
...
05/21/2020
Journal of Clinical Pathways
News
Integrated Palliative, Oncology Care for AML Improves PROs
05/15/2020
A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...
A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...
A...
05/15/2020
Journal of Clinical Pathways
Research in Review
End-of-Life Care Underutilized Among Older Patients With AML
08/10/2017
JCP Editors
Use of end-of-life care and hospice services is suboptimal among older patients with acute myeloid leukemia (AML), according to a recent study published in the Journal of Clinical Oncology (online August 7, 2017;...
Use of end-of-life care and hospice services is suboptimal among older patients with acute myeloid leukemia (AML), according to a recent study published in the Journal of Clinical Oncology (online August 7, 2017;...
Use of...
08/10/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Improves Survival in a Subtype of AML
08/04/2017
JCP Editors
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia (AML) and a specific mutation, according to research published in The New England...
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia (AML) and a specific mutation, according to research published in The New England...
...
08/04/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Works Better in AML Patients With Activated NK Cells
08/03/2017
JCP Editors
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...
The...
08/03/2017
Journal of Clinical Pathways
Research in Review
Prognostic Implications of ETS2 Expression in AML
07/25/2017
JCP Editors
Elevated expression levels of ETS2 were a strong predictor of prognosis in acute myeloid leukemia (AML) and should be used to guide treatment decisions, according to recent research published in Journal of...
Elevated expression levels of ETS2 were a strong predictor of prognosis in acute myeloid leukemia (AML) and should be used to guide treatment decisions, according to recent research published in Journal of...
...
07/25/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use